Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 2/2014

01.06.2014 | Systemic Therapy (J Cortes, Section Editor)

The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer

verfasst von: Esther Zamora, Eva Muñoz-Couselo, Javier Cortes, Jose Perez-Garcia

Erschienen in: Current Breast Cancer Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Recent advances in breast cancer research have allowed deconstruction of the molecular profile of the most relevant breast cancer subtypes. This has led to an increase in treatment options, including more personalized therapy and considerable improvements in patient outcomes. Although there are only a few targeted therapies approved for advanced breast cancer, several novel strategies targeting different tyrosine kinase receptors currently are under evaluation. Fibroblast growth factors and their receptors (FGFRs) are involved in different physiologic processes and also play a critical role in cancer cell proliferation and survival. This article focuses on the main molecular alterations of FGFRs, as well as the available preclinical and clinical data regarding FGFR inhibitors in breast cancer. In addition, we analyze the management of specific adverse events, such as hyperphosphatemia, and discuss unanswered questions regarding the clinical development of these agents.
Literatur
1.
2.
Comprehensive molecular portraits of human breast tumours. Nature. 490(7418):61–70.
3.
Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.PubMedCrossRef
4.
Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.PubMedCrossRef
5.
Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.PubMedCrossRef
6.
Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.PubMedCrossRef
7.
Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.PubMedCrossRef
8.•
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29. This review provides a complete global overview of the FGF/FGFR signaling pathway.PubMedCrossRef
9.
Haugsten EM et al. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8(11):1439–52.PubMedCrossRef
10.
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139–49.PubMedCrossRef
11.•
Wu YM et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–47. This article presents a good example of how the implementation of next-generation sequencing technologies will be critical for the detection of novel druggable oncogenic alterations in the coming years.PubMedCentralPubMedCrossRef
12.
Zhou L et al. Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis. Breast Cancer Res Treat. 2012;136(3):885–97.PubMedCrossRef
13.
Elbauomy Elsheikh S et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9(2):R23.PubMedCentralPubMedCrossRef
14.
Theillet C et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Gene Chromosome Cancer. 1993;7(4):219–26.CrossRef
15.
Ray ME et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res. 2004;64(1):40–7.PubMedCrossRef
16.
Kwek SS et al. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene. 2009;28(17):1892–903.PubMedCentralPubMedCrossRef
17.
Reis-Filho JS et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12(22):6652–62.PubMedCrossRef
18.
Turner N et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013–23.PubMedCentralPubMedCrossRef
19.
Shiang CY et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat. 2010;123(3):747–55.PubMedCrossRef
20.•
Andre F et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19(13):3693–702. This work integrates preclinical data in state-of-the-art, molecularly guided clinical trials, with the goal of using this information to develop more effective treatments.PubMedCrossRef
21.
Turner N et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70(5):2085–94.PubMedCentralPubMedCrossRef
22.
Tomlinson DC, Knowles MA, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer. 2012;130(12):2857–66.PubMedCrossRef
23.
Thussbas C et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24(23):3747–55.PubMedCrossRef
24.
Bange J et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62(3):840–7.PubMed
25.
Tenhagen M et al. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer. 2012;19(4):R115–29.PubMedCrossRef
26.
Bello E et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011;71(4):1396–405.PubMedCrossRef
27.
Soria JC et al. First-In-Man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumor. Ann Oncol. 2012;23(Supplement 1):i15–25.
28.
Garfield DH et al. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008;26(31):5131–2. author reply 5132–3.PubMedCrossRef
29.
30.•
Dienstmann R et al. Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Ann Oncol. 2012;23(Supplement 9):ix116–43. This study shows impressive antitumor activity of E-3810 in FGFR1-amplified breast cancer.
31.
Guagnano V et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118–33.PubMedCrossRef
32.
Wolf J et al. Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetivally preselected advanced solid tumors. Cancer Res. 2012;72(8):supl 1.
33.
Andre F, et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR); 2013, Apr 6–10; Washington DC. Abstr LB145.
34.
Lieu C et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130–9.PubMedCrossRef
35.
Hortobagyi GN et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J. Clin Oncol. 2013;31(suppl; abstr LBA509).
Metadaten
Titel
The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer
verfasst von
Esther Zamora
Eva Muñoz-Couselo
Javier Cortes
Jose Perez-Garcia
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 2/2014
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-013-0138-4

Weitere Artikel der Ausgabe 2/2014

Current Breast Cancer Reports 2/2014 Zur Ausgabe

Systemic Therapy (J Cortes, Section Editor)

Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy

Risk, Prevention, and Screening (TA Patel, Section Editor)

Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer

Risk, Prevention, and Screening (TA Patel, Section Editor)

Use of Exogenous Hormones and Risks of Breast and Ovarian Cancers in BRCA1/2 Mutation Carriers; Methodological and Clinical Considerations

Risk, Prevention, and Screening (TA Patel, Section Editor)

Breast Tomosynthesis: a Replacement or an Adjunct to Conventional Diagnostic Mammography?

Risk, Prevention, and Screening (TA Patel, Section Editor)

Targets for the Action of Phytoestrogens in Breast Cancer—Focus on Isoflavones and Resveratrol

Systemic Therapy (J Cortes, Section Editor)

Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise